NASDAQ
NRC
Last Price
US $22.34
KEY FIGURES
MKT CAP
$469.0M
EPS
TTM
$0.41
PEG
TTM
N/M
P/E
TTM
51.03x
P/S
TTM
3.41x
YIELD
2.88%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
National Research Corporation cash flow to debt ratio of 33.47% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.
Financial risk - Healthy cash flow growth.
National Research Corporation's free cash flow has decreased -17.90% from $19.18M last year to $15.74M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
National Research Corporation's debt to equity ratio is 5.78, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
National Research Corporation's debt has increased relative to shareholder equity from 2.06 last year to 5.78 today, signaling weakened financials
Financial stability - Net debt/EBITDA.
National Research Corporation has a net debt to EBITDA ratio of 2.48x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
National Research Corporation's interest coverage ratio of 3.82 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
National Research Corporation's profit margin has decreased (-62.39%) in the last year from 17.32% to 6.52%, signaling decreasing performance
Financial risk - Short term assets vs short term liabilities.
National Research Corporation's short-term liabilities of $36.62M exceed its short-term assets of $20.21M, signaling financial risk
Increasing performance - ROA.
National Research Corporation's return on assets of 6.71% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
National Research Corporation's return on equity of 57.24%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
National Research Corporation's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
National Research Corporation had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
National Research Corporation has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
National Research Corporation has a free cash flow yield of 3.36%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
National Research Corporation's yearly earnings has decreased -53.19% since last year from $24.78M to $11.60M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
National Research Corporation's yearly revenue has decreased -3.96% since last year from $143.06M to $137.39M, signaling decreasing performance
Increasing performance - ROIC.
ROIC 12.18% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
National Research Corporation's 3-year revenue CAGR of -3.22% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
National Research Corporation had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
National Research Corporation had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
National Research Corporation is overvalued relative to its fair value price of 0.74 based on Discounted Cash Flow model
Overvalued - Earnings yield.
National Research Corporation has an earnings yield of 1.99%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
Overvalued - EBITDA valuation.
National Research Corporation is overvalued relative to its fair value price of 6.02 based on EBITDA multiple model
Undervalued - EV/EBITDA.
National Research Corporation has an EV/EBITDA ratio of 19.54x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
National Research Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
National Research Corporation has a price-to-book ratio of 33.62x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Undervalued - P/S ratio.
National Research Corporation has a price-to-sales ratio of 3.38x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
57.24%
Return on equity
ROIC: 12.18%
Valuation History
51.0X
Price to Earnings
EV/EBITDA: 19.5X
Cash flow
Profit margin
0.61%
(FY vs FY)
EBITDA Y/Y
-9.86%
(FY vs FY)
Cash flow Y/Y
-15.55%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $22.34
-96.69%
Default assumptions
EBITDA Multiple
Fair Value
Market $22.34
-73.05%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.